Literature DB >> 35096256

Review on Novel Oral Therapies for Psoriasis.

Olga Marushchak1,2, Rose Yakubov1,2, Rebecca Yakubov1,2, Gary Goldenberg1,2.   

Abstract

Currently, several classes of oral therapies for psoriasis are in use, in development, or in investigative stages. Standard non-biologic treatments for psoriasis, such as methotrexate, cyclosporine, and acitretin, have generally unfavorable safety profiles and are not ideal for long-term use. This review will address the safety and efficacy of existing and novel oral therapies for psoriasis that target inflammatory pathways via modulation of phosphodiesterase 4 (PDE4), Janus kinases (JAKs), sphingosine 1-phosphate (S1P), A3 adenosine receptors, and rho-associated kinase 2 (ROCK2), with an emphasis on JAK inhibitors.
Copyright © 2021. Matrix Medical Communications. All rights reserved.

Entities:  

Keywords:  JAK inhibitors; Psoriasis; novel oral treatment

Year:  2021        PMID： 35096256      PMCID： PMC8794486     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN： 1941-2789


  38 in total

1.  Drug survival of apremilast in a real-world setting.

Authors:  Megumi Kishimoto; Mayumi Komine; Koji Kamiya; Junichi Sugai; Mamitaro Ohtsuki
Journal:  J Dermatol       Date:  2019-06-10       Impact factor: 4.005

2.  Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial.

Authors:  Andrea Vaclavkova; Sergio Chimenti; Petr Arenberger; Peter Holló; Paul-Gunther Sator; Michel Burcklen; Mylène Stefani; Daniele D'Ambrosio
Journal:  Lancet       Date:  2014-08-10       Impact factor: 79.321

3.  Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis.

Authors:  Robert Wolk; Ehrin J Armstrong; Peter R Hansen; Bruce Thiers; Shuping Lan; Anna M Tallman; Mandeep Kaur; Svitlana Tatulych
Journal:  J Clin Lipidol       Date:  2017-06-24       Impact factor: 4.766

Review 4.  Recommendations for Initiating Systemic Therapy in Patients with Psoriasis.

Authors:  George Martin; Melodie Young; Lakshi Aldredge
Journal:  J Clin Aesthet Dermatol       Date:  2019-04-01

5.  Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics.

Authors:  Jashin J Wu; Corey Pelletier; Brian Ung; Marc Tian; Ibrahim Khilfeh; Jeffrey R Curtis
Journal:  J Comp Eff Res       Date:  2020-07-08       Impact factor: 1.744

6.  Treatment of Plaque-Type Psoriasis With Oral CF101: Data from a Phase II/III Multicenter, Randomized, Controlled Trial.

Authors:  Michael David; Dimitar Konstantinov Gospodinov; Nicola Gheorghe; Grisha Stefanov Mateev; Mariyana Venelinova Rusinova; Evgeniya Hristakieva; Laura Gheuca Solovastru; Rita V Patel; Calin Giurcaneanu; Mariela Chepileva Hitova; Anca Ioana Purcaru; Beti Horia; Iliya Iliev Tsingov; Rumyana Kaloferova Yankova; Miroslava Ilieva Kadurina; Michal Ramon; Maria Rotaru; Olga Simionescu; Vasile Benea; Zdravka Velichkova Demerdjieva; Maria Rodica Cosgarea; Horia Silviu Morariu; Ziv Michael; Patricia Cristodor; Carmen Nica; Michael H Silverman; David R Bristol; Zivit Harpaz; Motti Farbstein; Shira Cohen; Pnina Fishman
Journal:  J Drugs Dermatol       Date:  2016-08-01       Impact factor: 2.114

7.  Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.

Authors:  Hervé Bachelez; Peter C M van de Kerkhof; Robert Strohal; Alexey Kubanov; Fernando Valenzuela; Joo-Heung Lee; Vladimir Yakusevich; Sergio Chimenti; Jocelyne Papacharalambous; James Proulx; Pankaj Gupta; Huaming Tan; Margaret Tawadrous; Hernan Valdez; Robert Wolk
Journal:  Lancet       Date:  2015-06-04       Impact factor: 79.321

8.  Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.

Authors:  Peter Schafer
Journal:  Biochem Pharmacol       Date:  2012-01-10       Impact factor: 5.858

9.  Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis.

Authors:  Fangyuan Tian; Zhaoyan Chen; Ting Xu
Journal:  J Int Med Res       Date:  2019-05-17       Impact factor: 1.671

10.  Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients.

Authors:  Matthew T Patrick; Philip E Stuart; Kalpana Raja; Johann E Gudjonsson; Trilokraj Tejasvi; Jingjing Yang; Vinod Chandran; Sayantan Das; Kristina Callis-Duffin; Eva Ellinghaus; Charlotta Enerbäck; Tõnu Esko; Andre Franke; Hyun M Kang; Gerald G Krueger; Henry W Lim; Proton Rahman; Cheryl F Rosen; Stephan Weidinger; Michael Weichenthal; Xiaoquan Wen; John J Voorhees; Gonçalo R Abecasis; Dafna D Gladman; Rajan P Nair; James T Elder; Lam C Tsoi
Journal:  Nat Commun       Date:  2018-10-09       Impact factor: 14.919
View more
  1 in total

Review 1.  Dermatologic Disease-Directed Targeted Therapy (D3T2): The Application of Biomarker-Based Precision Medicine for the Personalized Treatment of Skin Conditions-Precision Dermatology.

Authors:  Philip R Cohen; Razelle Kurzrock
Journal:  Dermatol Ther (Heidelb)       Date:  2022-09-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.